JBIO
NA
$9.80
-$0.05(-0.51%)
57
Overall
80
Value
72
Tech
21
Quality
Market Cap
$319.42M
Volume
484.56K
52W Range
$6.57 - $100.28
Target Price
$19.00
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||
| Operating Expenses | $23.0M | $53.2M | $81.4M | $74.6M | ||
| Research & Development | $15.0M | $38.6M | $64.2M | $53.2M | ||
| Research Expense | $15.0M | $38.6M | $64.2M | $53.2M | ||
| Selling, General & Administrative | $8.0M | $14.6M | $17.2M | $21.4M | ||
| General & Administrative Expenses | $8.0M | $14.6M | $17.2M | $21.4M | ||
| Salaries & Wages | $2.0M | $5.5M | $21.2M | $19.5M | ||
| Depreciation & Amortization | -- | $407.0K | -- | -- | ||
| Other Operating Expenses | $-253.0K | $-461.0K | $-1.1M | $-950.0K | ||
| OPERATING INCOME | ||||||
| Operating income | $-23.0M | $-53.2M | $-81.4M | $-74.6M | ||
| EBITDA | $-22.9M | $-53.2M | $-78.4M | $-71.5M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | $65.0K | $1.8M | $5.9M | $5.0M | ||
| Net Non-Operating Interest Income/Expense | $65.0K | $1.8M | $5.9M | $5.0M | ||
| Gain on Sale of Securities | $113.2M | -- | -- | -- | ||
| Other Income/Expense | $3.0K | $-79.0K | $-702.0K | $151.0K | ||
| Other Special Charges | $-3.0K | $-79.0K | $-1.0K | $-19.0K | ||
| SPECIAL ITEMS | ||||||
| Restructring And Mn A Income | -- | -- | -- | $6.7M | ||
| Special Income Charges | -- | -- | -- | $-6.7M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $256.0K | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-22.9M | $-53.2M | $-75.5M | $-69.6M | ||
| Pre-Tax Income | $-23.0M | $-51.5M | $-75.5M | $-69.6M | ||
| INCOME TAX | ||||||
| Tax Provision | $3.0K | $25.0K | $56.0K | $55.0K | ||
| NET INCOME | ||||||
| Net Income | $-23.0M | $-51.5M | $-75.5M | $-69.6M | ||
| Net Income (Continuing Operations) | $-23.0M | $-51.5M | $-75.5M | $-69.6M | ||
| Net Income (Discontinued Operations) | $-23.0M | $-51.5M | $-75.5M | $-69.6M | ||
| Net Income (Common Stockholders) | $-23.0M | $-51.5M | $-75.5M | $-69.6M | ||
| Normalized Income | $-18.1M | -- | -- | $-61.9M | ||
| TOTALS | ||||||
| Total Expenses | $23.0M | $53.2M | $81.4M | $74.6M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $351.2K | $24.5M | $26.3M | $28.6M | ||
| Average Shares Outstanding (Diluted) | -- | $24.5M | $26.3M | $28.6M | ||
| Shares Outstanding | $697.4K | $24.8M | $32.6M | $29.0M | ||
| Basic EPS | $-65.45 | $-2.1 | $-2.87 | $-2.44 | ||
| Basic EPS (Continuing Operations) | $-65.45 | $-2.1 | $-2.87 | $-2.44 | ||
| Diluted EPS | $-65.45 | $-2.1 | $-2.87 | $-2.44 | ||
| Diluted EPS (Continuing Operations) | -- | $-2.1 | $-2.87 | $-2.44 | ||
| OTHER METRICS | ||||||
| Accretion On Preferred Stock | $22.0K | -- | -- | -- | ||
| Depletion | -- | $407.0K | -- | -- | ||
| Interest Expense Operating | $59.0K | -- | -- | -- | ||
| Other Gand A | $8.0M | $14.6M | $17.2M | $21.4M | ||
| Otherunder Preferred Stock Dividend | $22.0K | -- | -- | -- | ||
| Preferred Stock Dividends | $22.0K | -- | -- | -- | ||
| Restruct | -- | -- | -- | $6.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JBIO | $9.80 | -0.5% | 484.56K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |